



Gastroenterology Enrollment Form

Phone: 713-360-2100 or 1-855-497-7956 | Fax: 713-360-2105 or 1-855-497-7957

Ship To: Patient Physician Other Ship By: _____

Patient Information

Name: _____
 DOB: _____ Gender: M F SSN: _____
 Language: Eng Span Other: _____ Weight: _____ Lbs Kgs
 Address: _____
 City: _____ State: _____ Zip: _____
 Home #: _____ Work #: _____
 Cell #: _____
 Allergies: _____ NKDA

Prescriber Information

Prescriber: _____
 DEA: _____ NPI: _____
 Address: _____
 City: _____ State: _____ Zip: _____
 Phone #: _____
 Cell #: _____ Fax #: _____
 Office Contact: _____
 Initiate Appeal Reason: _____

**** INSURANCE INFORMATION: PLEASE FAX COPY OF PRESCRIPTION CARD, FRONT AND BACK AS WELL AS ALL CLINIC NOTES ****

Clinical Information

DIAGNOSIS (Description & ICD 10 Code): _____ **Current Medications:** _____

Has Patient been treated previously for this condition Yes No

NSAIDS _____	Duration: _____	Sulfasalazine _____	Duration: _____
Corticosteroids _____	Duration: _____	5-ASA (5-aminosalicylates) _____	Duration: _____
MTX _____	Duration: _____	6-MP (6-mercaptopurine) _____	Duration: _____
Azathioprine _____	Duration: _____	REMICADE infusion _____	Duration: _____
Other prior BIOLOGIC use: _____	Duration: _____	Other: _____	Duration: _____

Number of ENDOSCOPIES _____

Is Patient currently on any therapy? Yes No List Meds: _____

Will patient stop taking Meds before starting new meds? Yes No If Yes: _____

Has patient received PPD? Yes No Results: _____

Medication	Strength	Directions	QTY	Refill	
Cimzia	Starter: 200mg Prefilled Syringe Starter Kit (6 doses) 200mg Vial X 3 Cartons (6 doses)	Inject TWO 200mg (400mg) subcutaneously at weeks 0, 2 and 4	4 week supply	0	
	Maintenance: 200mg Prefilled Syringe Starter Kit (2 doses) 200mg Prefilled Syringe (2 doses / kit)	Inject TWO 200mg (400mg) subcutaneously every 4 weeks Inject 200mg subcutaneously every 2 weeks	4 week supply		
Entyvio	Initial: 300mg Vial	Infuse 300mg IV over 30 minutes at week 0, 2 and 6 Include Sterile Water diluent and 250ml NaCl for infusion	3	0	
	Maintenance: 300mg Vial	Infuse 300mg IV over 30 minutes every 8 weeks Include Sterile Water diluent and 250ml NaCl for infusion	1		
Humira	Starter: Crohn's/UC Starter Pack	Inject 160 mg subcutaneously on Day 1, then 80 mg on Day 15 Inject 80 mg subcutaneously on Day 1 and Day 2 consecutively, then 80 mg on Day 15	1 kit	0	
	Maintenance: 40mg Pen (2 doses / kit) 40mg Prefilled Syringe (2 doses / kit)	Inject 40mg subcutaneously every other week	1 kit		
Remicade Inflectra	Initial: 100mg Vial	Infuse _____ mg/kg = _____ mg at 0, 2, and 6 weeks	Pharmacist to QS	0	
	Maintenance: 100mg Vial	Infuse _____ mg/kg = _____ mg every _____ weeks	Pharmacist to QS		
Simponi	Starter: 100mg SmartJect 100mg Prefilled Syringe	Inject TWO 100mg (200mg) subcutaneously at week 0, then 100mg on week 2	3	0	
	Maintenance: 100mg SmartJect 100mg Prefilled Syringe	Inject 100mg subcutaneously every 4 weeks	1		
Stelara	Initial IV:	Weight Up to 55 kg	Infuse 260 mg (2 vials) intravenously X 1 at week 0	2	Zero
		Greater than 55 kg to 85 kg	Infuse 390 mg (3 vials) intravenously X 1 at week 0	3	
		Greater than 85 kg	Infuse 520 mg (4 vials) intravenously X 1 at week 0	4	
Maintenance SQ:	All Weights	Inject 90 mg subcutaneously 8 weeks after intial intravenous dose, then every 8 weeks thereafter	1		
Xeljanz	Starter: 10 mg tab	Take 1 tablet PO 2 times a day for 8 weeks	8 week supply	0	
	Maintenance: 5 mg tab 10 mg tab	Take 1 tablet PO 2 times a day	4 week supply		
Xifaxan	550mg Tab	Take 1 tablet PO 2 times a day	60	0	
		Take 1 tablet 3 times a day X 14 days	42		

Additional Information: _____

IMPORTANT NOTICE: This fax is intended to be delivered only to the named addressee. It contains material that is confidential, privileged, proprietary or exempt from disclosure under applicable law. If you are not the named addressee, you should not disseminate, distribute, or copy this fax. Please notify the sender immediately if you have received this document in error and then destroy this document immediately.

Prescriber Signature: _____

Date: _____

I certify that the use of the indicated treatment is medically necessary and I will be supervising the patient's treatment. By signing this form and utilizing our services, you are authorizing BioCure LLC and its employees to serve as your prior authorization designated agent in dealing with medical and prescription insurance companies and Co-pay Assistance Foundations